CDR / Formulary

In Canada, Pharmacoeconomic (health economic) analysis is an essential requirement for drug submissions to most regulatory bodies, such as provincial formularies, the Common Drug Review (CDR), and some private drug plan administrators. As such, it plays an important role in the success and acceptance of a drug.

Brogan Inc. provides data and expertise to evaluate the cost-effectiveness of treating the conditions addressed by your new drug compared to the gold standard of therapy currently available for patients.

Our experienced staff will prepare the economic submissions needed to facilitate provincial and private drug plan listings for your products.

For more information, please call our Health Economics department at 613.599.0711.